<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03624920</url>
  </required_header>
  <id_info>
    <org_study_id>THN102-202</org_study_id>
    <nct_id>NCT03624920</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of THN102 in Patients With Parkinson's Disease and Excessive Daytime Sleepiness</brief_title>
  <official_title>Safety and Efficacy of THN102 in Patients With Parkinson's Disease and Excessive Daytime Sleepiness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theranexus</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theranexus</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, placebo-controlled, 3-way cross-over phase IIa trial comparing two dose&#xD;
      levels of THN102 to placebo in patients suffering from Parkinson's disease associated with&#xD;
      excessive daytime sleepiness.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The treatment duration is 2 weeks per period. Each treatment period is followed by a one-week&#xD;
      washout period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 12, 2018</start_date>
  <completion_date type="Actual">February 24, 2020</completion_date>
  <primary_completion_date type="Actual">December 20, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Complete 3 way-Crossover</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Adverse Events</measure>
    <time_frame>2 weeks</time_frame>
    <description>Number of participants with spontaneously reported treatment-related adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Epworth Sleeping Scale (ESS)</measure>
    <time_frame>2 weeks</time_frame>
    <description>Range of the scale : 0 to 24. A low score indicates a good outcome. Results shown are corresponding to a change from baseline of the ESS score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychomotor Vigilance Test (PVT) : Reaction Time (Miliseconds) Change From Baseline</measure>
    <time_frame>2 weeks</time_frame>
    <description>PVT measures reaction time in milliseconds. The results below are corresponding to the reaction time change from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montreal Cognitive Assessment Battery (MoCA)</measure>
    <time_frame>2 weeks</time_frame>
    <description>MoCA score reflects the cognitive capacities of a person. Range of the total score of 10 test items: 0 to 30 points. A high score indicates good cognitive functioning. A score of 26 and above is considered normal.&#xD;
The results below are shown as change from baseline of the MoCA score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy in Improving Sleepiness (ESS). Responders Rate, Change From Baseline</measure>
    <time_frame>2 weeks</time_frame>
    <description>ESS score responder rate, defined as the proportion of subjects with at least 25% ESS improvement from baseline, at the end of each treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy in Improving Sleepiness (ESS). Patients in Remission, Change From Baseline</measure>
    <time_frame>2 weeks</time_frame>
    <description>Number of patients in remission (=without residual sleepiness), i.e. ESS &lt; 11 at the end of each treatment period</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>THN102 Dosage A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>THN102 Dosage A is a Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>THN102 Dosage B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>THN102 Dosage B : 200 mg/2 mg THN102 is a combination of modafinil 100mg and flecainide 1 mg daily dosage is 200 mg of modafinil and 2 mg of flecainide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>THN102 Dosage C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>THN102 Dosage C : 200 mg/18 mg THN102 is a combination of modafinil 100mg and flecainide 9 mg daily dosage is 200 mg of modafinil and 18 mg of flecainide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>THN102 Dosage A</intervention_name>
    <description>THN102 Dosages A: placebo</description>
    <arm_group_label>THN102 Dosage A</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>THN102 Dosage B</intervention_name>
    <description>THN102 Dosage B : 200mg/2mg</description>
    <arm_group_label>THN102 Dosage B</arm_group_label>
    <other_name>Dosage B</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>THN102 Dosage C</intervention_name>
    <description>THN102 Dosage C: 200mg/18mg</description>
    <arm_group_label>THN102 Dosage C</arm_group_label>
    <other_name>Dosage C</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects with a diagnosis of idiopathic Parkinson's disease as defined by the Movement&#xD;
             Disorders Society (MDS).&#xD;
&#xD;
          -  Subjects with Hoehn and Yahr scale score ≤ 4.&#xD;
&#xD;
          -  Body mass index &gt; 18 kg/m2 and &lt; 35 kg/m2.&#xD;
&#xD;
          -  Subjects should have a complaint of daytime sleepiness impacting their quality of life&#xD;
             and/or daytime functioning (e.g. falling asleep while reading or watching television,&#xD;
             while eating or talking with other people).&#xD;
&#xD;
          -  Epworth Sleepiness Scale (ESS) score ≥ 14.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with known or with a suspected sleep apnea syndrome or who have any other&#xD;
             cause of excessive daytime sleepiness, such as shift work sleep disorder.&#xD;
&#xD;
          -  Psychiatric and neurological disorders (other than Parkinson's disease),&#xD;
&#xD;
          -  Cardiovascular disorders such as - but not limited to&#xD;
&#xD;
          -  Uncontrolled moderate to severe hypertension&#xD;
&#xD;
          -  History or current diagnosis of electrocardiogram (ECG) abnormalities indicating&#xD;
             significant risk of safety for patients participating in the study&#xD;
&#xD;
          -  Recent myocardial infarction&#xD;
&#xD;
          -  Stable or unstable angina pectoris&#xD;
&#xD;
          -  Cardiac insufficiency or history of heart failure&#xD;
&#xD;
          -  Previous history of cardiac valvular surgery&#xD;
&#xD;
          -  Subjects with current impulse control disorder.&#xD;
&#xD;
          -  Subjects showing dementia or with MoCA &lt; 23.&#xD;
&#xD;
          -  Subjects with current suicidal risk&#xD;
&#xD;
          -  Current or recent (within one year) history of substance abuse or dependence disorder&#xD;
&#xD;
          -  Other active clinically significant illness&#xD;
&#xD;
          -  Subjects with hepatic or renal impairment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Christophe Corvol, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Hôpital La Pitié-Salpêtrière, 75651 Paris, France, Tel. +33 1 42 16 57 66, mail: jean-christophe.corvol@aphp.fr</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MGH Neurological Clinical Research Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>I. neurologická klinika Fakultní nemocnice u sv. Anny</name>
      <address>
        <city>Brno</city>
        <zip>65691</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologická klinika Fakultní nemocnice Hradec Králové</name>
      <address>
        <city>Hradec Králové</city>
        <zip>50005</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologická klinika Fakultní nemocnice Ostrava</name>
      <address>
        <city>Ostrava Poruba</city>
        <zip>70852</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut neuropsychiatrické péče</name>
      <address>
        <city>Praga 8</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologická klinika 1.LF UK a VFN v Praze</name>
      <address>
        <city>Praha 2</city>
        <zip>12821</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NEURO - Praha, s.r.o.</name>
      <address>
        <city>Praha 4</city>
        <zip>14000</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Axon Clinical, s.r.o.</name>
      <address>
        <city>Praha 5</city>
        <zip>15030</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologické oddělení Nemocnice Na Homolce</name>
      <address>
        <city>Praha 5</city>
        <zip>15030</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital NEurologique Pierre Wertheimer</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Hopital Salengro</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de la Timone Service de Neuro et pathologie du mouvement</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Guy de Chauliac</name>
      <address>
        <city>Montpellier</city>
        <zip>34195</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICM Centre d'Investigation Clinique Hôpital Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Purpan CIC Hall D 2eme etage</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Safavi, Neuroakademie Alzenau</name>
      <address>
        <city>Alzenau In Unterfranken</city>
        <zip>63755</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin, Klinik für Neurologie, Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologische Praxis Dipl. med. Christian Oehlwein</name>
      <address>
        <city>Gera</city>
        <zip>05551</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmakologisches Studienzentrum Chemnitz</name>
      <address>
        <city>Mittweida</city>
        <zip>09648</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Technische Universität München, Klinikum rechts der Isar, Neurologische Klinik und Poliklinik, Neuro-Kopf-Zentrum</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. med. Arnfin Bergmann</name>
      <address>
        <city>Neuburg</city>
        <zip>86633</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurozentrum Sophienstrasse</name>
      <address>
        <city>Stuttgart</city>
        <zip>70178</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NeuroPoint</name>
      <address>
        <city>Ulm</city>
        <zip>89073</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Dr. med. Joachim Springub / Wolfgang Schwarz, Studienzentrum Nord-West, *ausgelagerte Praxisräume:</name>
      <address>
        <city>Westerstede</city>
        <zip>26655</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nyírő Gyula Országos Pszichiátriai és Addiktológiai Intézet, Neurológiai Osztály</name>
      <address>
        <city>Budapest</city>
        <zip>1135</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Észak-Közép-budai Centrum</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Kenézy Gyula Egyetemi Kórház Neurológiai Osztály</name>
      <address>
        <city>Debrecen</city>
        <zip>4031</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Borsod-Abaúj-Zemplén Megyei Központi Kórház és Egyetemi Oktató Kórház, Stroke, Vascularis és Általános Neurológiai és Toxikológiai Osztály</name>
      <address>
        <city>Miskolc</city>
        <zip>3526</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PTE KK Neurológiai Klinika</name>
      <address>
        <city>Pécs</city>
        <zip>7623</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szegedi Tudományegyetem ÁOK Szent-Györgyi Albert Klinikai Központ Neurológiai Klinika</name>
      <address>
        <city>Szeged</city>
        <zip>6725</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Theranexus Investigational site</name>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>July 10, 2018</study_first_submitted>
  <study_first_submitted_qc>August 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2018</study_first_posted>
  <results_first_submitted>September 27, 2020</results_first_submitted>
  <results_first_submitted_qc>November 27, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 1, 2020</results_first_posted>
  <last_update_submitted>November 27, 2020</last_update_submitted>
  <last_update_submitted_qc>November 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Disorders of Excessive Somnolence</mesh_term>
    <mesh_term>Sleepiness</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 27, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/20/NCT03624920/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 21, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/20/NCT03624920/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>105 patients were screened and 77 were randomized and allowed to start the medications periods.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Sequence ABC</title>
          <description>A : 2 weeks under Placebo&#xD;
B : 2 weeks under THN102 200/2 (200mg modafinil and 2 mg of flecainide per os daily)&#xD;
C : 2 weeks under THN102 200/18 (200mg modafinil and 18 mg of flecainide per os daily)</description>
        </group>
        <group group_id="P2">
          <title>Sequence BCA</title>
          <description>A : 2 weeks under Placebo&#xD;
B : 2 weeks under THN102 200/2 (200mg modafinil and 2 mg of flecainide per os daily)&#xD;
C : 2 weeks under THN102 200/18 (200mg modafinil and 18 mg of flecainide per os daily)</description>
        </group>
        <group group_id="P3">
          <title>Sequence CAB</title>
          <description>A : 2 weeks under Placebo&#xD;
B : 2 weeks under THN102 200/2 (200mg modafinil and 2 mg of flecainide per os daily)&#xD;
C : 2 weeks under THN102 200/18 (200mg modafinil and 18 mg of flecainide per os daily)</description>
        </group>
        <group group_id="P4">
          <title>Sequence ACB</title>
          <description>A : 2 weeks under Placebo&#xD;
B : 2 weeks under THN102 200/2 (200mg modafinil and 2 mg of flecainide per os daily)&#xD;
C : 2 weeks under THN102 200/18 (200mg modafinil and 18 mg of flecainide per os daily)</description>
        </group>
        <group group_id="P5">
          <title>Sequence CBA</title>
          <description>A : 2 weeks under Placebo&#xD;
B : 2 weeks under THN102 200/2 (200mg modafinil and 2 mg of flecainide per os daily)&#xD;
C : 2 weeks under THN102 200/18 (200mg modafinil and 18 mg of flecainide per os daily)</description>
        </group>
        <group group_id="P6">
          <title>Sequence BAC</title>
          <description>A : 2 weeks under Placebo&#xD;
B : 2 weeks under THN102 200/2 (200mg modafinil and 2 mg of flecainide per os daily)&#xD;
C : 2 weeks under THN102 200/18 (200mg modafinil and 18 mg of flecainide per os daily)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>mITT</population>
      <group_list>
        <group group_id="B1">
          <title>Sequence ABC</title>
          <description>A : 2 weeks under Placebo&#xD;
B : 2 weeks under THN102 200/2 (200mg modafinil and 2 mg of flecainide per os daily)&#xD;
C : 2 weeks under THN102 200/18 (200mg modafinil and 18 mg of flecainide per os daily)</description>
        </group>
        <group group_id="B2">
          <title>Sequence BCA</title>
          <description>A : 2 weeks under Placebo&#xD;
B : 2 weeks under THN102 200/2 (200mg modafinil and 2 mg of flecainide per os daily)&#xD;
C : 2 weeks under THN102 200/18 (200mg modafinil and 18 mg of flecainide per os daily)</description>
        </group>
        <group group_id="B3">
          <title>Sequence CAB</title>
          <description>A : 2 weeks under Placebo&#xD;
B : 2 weeks under THN102 200/2 (200mg modafinil and 2 mg of flecainide per os daily)&#xD;
C : 2 weeks under THN102 200/18 (200mg modafinil and 18 mg of flecainide per os daily)</description>
        </group>
        <group group_id="B4">
          <title>Sequence ACB</title>
          <description>A : 2 weeks under Placebo&#xD;
B : 2 weeks under THN102 200/2 (200mg modafinil and 2 mg of flecainide per os daily)&#xD;
C : 2 weeks under THN102 200/18 (200mg modafinil and 18 mg of flecainide per os daily)</description>
        </group>
        <group group_id="B5">
          <title>Sequence CBA</title>
          <description>A : 2 weeks under Placebo&#xD;
B : 2 weeks under THN102 200/2 (200mg modafinil and 2 mg of flecainide per os daily)&#xD;
C : 2 weeks under THN102 200/18 (200mg modafinil and 18 mg of flecainide per os daily)</description>
        </group>
        <group group_id="B6">
          <title>Sequence BAC</title>
          <description>A : 2 weeks under Placebo&#xD;
B : 2 weeks under THN102 200/2 (200mg modafinil and 2 mg of flecainide per os daily)&#xD;
C : 2 weeks under THN102 200/18 (200mg modafinil and 18 mg of flecainide per os daily)</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="13"/>
            <count group_id="B4" value="13"/>
            <count group_id="B5" value="9"/>
            <count group_id="B6" value="11"/>
            <count group_id="B7" value="72"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race : White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="11"/>
                    <measurement group_id="B7" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Race Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ethnicity : Not hispanic or latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="11"/>
                    <measurement group_id="B7" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ethnicity : Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ethnicity : not reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety Adverse Events</title>
        <description>Number of participants with spontaneously reported treatment-related adverse events</description>
        <time_frame>2 weeks</time_frame>
        <population>Overall number of participant reported corresponds to the safety set population of the clinical report</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>THN102 Placebo (Dosage A)</description>
          </group>
          <group group_id="O2">
            <title>THN102 200/2</title>
            <description>THN102 200 mg/2 mg (Dosage B)</description>
          </group>
          <group group_id="O3">
            <title>THN102 200/18</title>
            <description>THN102 200 mg/18 mg (Dosage C)</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Adverse Events</title>
          <description>Number of participants with spontaneously reported treatment-related adverse events</description>
          <population>Overall number of participant reported corresponds to the safety set population of the clinical report</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects with at least one TEAE leading to death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject with at least one serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with at least one related serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with at least one TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with at least one related TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with at least one TEAE leading to discont</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with at least one related TEAE leading to</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with at least one serious TEAE leading to</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Epworth Sleeping Scale (ESS)</title>
        <description>Range of the scale : 0 to 24. A low score indicates a good outcome. Results shown are corresponding to a change from baseline of the ESS score.</description>
        <time_frame>2 weeks</time_frame>
        <population>modified intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>THN102 Placebo (Dosage A)</description>
          </group>
          <group group_id="O2">
            <title>THN102 200/2</title>
            <description>THN102 200 mg/2 mg (Dosage B)</description>
          </group>
          <group group_id="O3">
            <title>THN102 200/18</title>
            <description>THN102 200 mg/18 mg (Dosage C)</description>
          </group>
        </group_list>
        <measure>
          <title>Epworth Sleeping Scale (ESS)</title>
          <description>Range of the scale : 0 to 24. A low score indicates a good outcome. Results shown are corresponding to a change from baseline of the ESS score.</description>
          <population>modified intent to treat</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4422" spread="0.5117"/>
                    <measurement group_id="O2" value="-3.8417" spread="0.5086"/>
                    <measurement group_id="O3" value="-3.1850" spread="0.4982"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Psychomotor Vigilance Test (PVT) : Reaction Time (Miliseconds) Change From Baseline</title>
        <description>PVT measures reaction time in milliseconds. The results below are corresponding to the reaction time change from baseline.</description>
        <time_frame>2 weeks</time_frame>
        <population>PVT full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>THN102 Placebo (Dosage A)</description>
          </group>
          <group group_id="O2">
            <title>THN102 200/2</title>
            <description>THN102 200 mg/2 mg (Dosage B)</description>
          </group>
          <group group_id="O3">
            <title>THN102 200/18</title>
            <description>THN102 200 mg/18 mg (Dosage C)</description>
          </group>
        </group_list>
        <measure>
          <title>Psychomotor Vigilance Test (PVT) : Reaction Time (Miliseconds) Change From Baseline</title>
          <description>PVT measures reaction time in milliseconds. The results below are corresponding to the reaction time change from baseline.</description>
          <population>PVT full analysis set</population>
          <units>millisecond (msec)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.2201" spread="10.0565"/>
                    <measurement group_id="O2" value="-24.1089" spread="9.9393"/>
                    <measurement group_id="O3" value="-19.6450" spread="9.8847"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Montreal Cognitive Assessment Battery (MoCA)</title>
        <description>MoCA score reflects the cognitive capacities of a person. Range of the total score of 10 test items: 0 to 30 points. A high score indicates good cognitive functioning. A score of 26 and above is considered normal.&#xD;
The results below are shown as change from baseline of the MoCA score.</description>
        <time_frame>2 weeks</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>THN102 Placebo (Dosage A)</description>
          </group>
          <group group_id="O2">
            <title>THN102 200/2</title>
            <description>THN102 200 mg/2 mg (Dosage B)</description>
          </group>
          <group group_id="O3">
            <title>THN102 200/18</title>
            <description>THN102 200 mg/18 mg (Dosage C)</description>
          </group>
        </group_list>
        <measure>
          <title>Montreal Cognitive Assessment Battery (MoCA)</title>
          <description>MoCA score reflects the cognitive capacities of a person. Range of the total score of 10 test items: 0 to 30 points. A high score indicates good cognitive functioning. A score of 26 and above is considered normal.&#xD;
The results below are shown as change from baseline of the MoCA score.</description>
          <population>mITT</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2240" spread="0.1935"/>
                    <measurement group_id="O2" value="0.03267" spread="0.1923"/>
                    <measurement group_id="O3" value="0.4251" spread="0.1900"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy in Improving Sleepiness (ESS). Responders Rate, Change From Baseline</title>
        <description>ESS score responder rate, defined as the proportion of subjects with at least 25% ESS improvement from baseline, at the end of each treatment period</description>
        <time_frame>2 weeks</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>THN102 Placebo (Dosage A)</description>
          </group>
          <group group_id="O2">
            <title>THN102 200/2</title>
            <description>THN102 200 mg/2 mg (Dosage B)</description>
          </group>
          <group group_id="O3">
            <title>THN102 200/18</title>
            <description>THN102 200 mg/18 mg (Dosage C)</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy in Improving Sleepiness (ESS). Responders Rate, Change From Baseline</title>
          <description>ESS score responder rate, defined as the proportion of subjects with at least 25% ESS improvement from baseline, at the end of each treatment period</description>
          <population>mITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy in Improving Sleepiness (ESS). Patients in Remission, Change From Baseline</title>
        <description>Number of patients in remission (=without residual sleepiness), i.e. ESS &lt; 11 at the end of each treatment period</description>
        <time_frame>2 weeks</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>THN102 Placebo (Dosage A)</description>
          </group>
          <group group_id="O2">
            <title>THN102 200/2</title>
            <description>THN102 200 mg/2 mg (Dosage B)</description>
          </group>
          <group group_id="O3">
            <title>THN102 200/18</title>
            <description>THN102 200 mg/18 mg (Dosage C)</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy in Improving Sleepiness (ESS). Patients in Remission, Change From Baseline</title>
          <description>Number of patients in remission (=without residual sleepiness), i.e. ESS &lt; 11 at the end of each treatment period</description>
          <population>mITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AE collection through study duration, starts with screening until follow up visit (last phone call), a total of 13 weeks.</time_frame>
      <desc>Listing of AEs reported are corresponding to TEAEs (treatment emergent adverse event) collected from randomization to last visit</desc>
      <group_list>
        <group group_id="E1">
          <title>THN102 Placebo</title>
          <description>THN102 Placebo (Dosage A)</description>
        </group>
        <group group_id="E2">
          <title>THN102 200/2</title>
          <description>THN102 200 mg/2 mg (Dosage B)</description>
        </group>
        <group group_id="E3">
          <title>THN102 200/18</title>
          <description>THN102 200 mg/18 mg (Dosage C)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (21.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>CONTUSION</sub_title>
                <description>wrist contusion and low back pain after fall</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (21.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle spasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Nightmare</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Theranexus</organization>
      <phone>+33680026779</phone>
      <email>werner.rein@theranexus.fr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

